Le Lézard
Classified in: Health
Subject: MRR

Interstitial cystitis (IC) drugs market size to increase by USD 369.58 million: Analysis of major players as well as the key contributor region - Technavio

North America will account for 35% of the global interstitial cystitis (IC) drugs market

NEW YORK, Jan. 30, 2023 /PRNewswire/ -- North America will account for 35% of the global Interstitial cystitis (IC) drugs market growth. The increasing cases of interstitial cystitis and the rise in research funding are driving the growth of the regional market. The Interstitial Cystitis Drugs Market by Type, Distribution Channel, and Geography - Forecast and Analysis 2023-2027 report has been published by Technavio. Market growth is estimated to accelerate at a CAGR of 5.9% and register an incremental growth of USD 369.58 million during the forecast period. The report provides a comprehensive analysis of growth opportunities at regional levels, new product launches, the latest trends, and the post-pandemic recovery of the global market. Download a PDF Sample Report

Company Profiles

The interstitial cystitis (IC) drugs market report includes information on the key products and recent developments of leading vendors, including:

Market Dynamics

The market is driven by factors such as the high prevalence of interstitial cystitis, increasing awareness of interstitial cystitis, and increasing grants for research on interstitial cystitis. However, the lack of approved drugs is hindering the market growth.

Competitive Analysis

The competitive scenario categorizes companies based on various performance indicators. Some of the factors considered include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, and growth in market share, among others. Request a Sample

Market Segmentation

Related Reports:

Chronic Obstructive Pulmonary Disease Drugs Market by Product, Distribution Channel and Geography - Forecast and Analysis 2023-2027: The chronic obstructive pulmonary disease drugs market is estimated to grow at a CAGR of 6.09% between 2022 and 2027. The size of the market is forecast to increase by USD 6,654.49 million. The rising prevalence of COPD is notably driving the market growth, although factors such as the high cost of conducting clinical trials in COPD may impede the market growth.

Allergy Immunotherapies Market by Product, Type, and Geography - Forecast and Analysis 2023-2027: The allergy immunotherapies market is estimated to grow at a CAGR of 8.95% between 2022 and 2027. The size of the market is forecast to increase by USD 1,010.37 million. The increasing prevalence of allergies is notably driving the market growth, although factors such as trial failures may impede the market growth.

Technavio's library includes over 17,000+ reports, covering more than 2,000 emerging technologies. Subscribe to our "Basic Plan" at just USD 5,000 and get lifetime access to Technavio Insights

What are the key data covered in this interstitial cystitis (IC) drugs market report?

Interstitial Cystitis Drugs Market Scope

Report Coverage


Page number


Base year


Historic period


Forecast period


Growth momentum & CAGR

Accelerate at a CAGR of 5.9%

Market growth 2023-2027

USD 369.58 million

Market structure


YoY growth 2022-2023(%)


Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 35%

Key countries

US, UK, Germany, Japan, and China

Competitive landscape

Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks

Key companies profiled

Allergan, Amneal Pharmaceuticals Inc., Astellas Pharma Inc., Aurobindo Pharma Ltd., Bayer AG, Cadila Healthcare Ltd., Eli Lilly and Co., Hikma Pharmaceuticals Plc, Intas Pharmaceuticals Ltd., Johnson and Johnson, Kyorin Pharmaceutical Co. Ltd., Mission Pharmacal Co., Perrigo Co. Plc, Pfizer Inc., Purdue Pharma LP, Seikagaku Corp., Sun Pharmaceutical Industries Ltd., Taro Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc.

Market dynamics

Parent Market Analysis; Market growth inducers and obstacles; Fast-growing and slow-growing segment analysis for the forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Browse for Technavio "Health Care" Research Reports

Table of Content

1 Executive Summary

2 Market Landscape

3 Market Sizing

4 Five Forces Analysis

5 Market Segmentation by Type

6 Customer landscape

7 Geographic Landscape

8 Drivers, Challenges, and Trends

9 Vendor Landscape

10 Vendor Analysis

11 Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio

These press releases may also interest you

at 05:45
The "Contact Lens Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Modality (Reusable, Disposable), By Design (Spherical, Toric, Multifocal and Others), By Material Type, By Application, By Distribution...

at 05:30
The "The Market and Future Potential for Molecular Point of Care (mPOC), 2023" report has been added to ResearchAndMarkets.com's offering. This report is an essential tool for understanding the size and growth opportunity in molecular POC. Molecular...

at 05:27
Noul Co. Ltd (CEO : David Lim) announced that it has signed an agreement with The RIGHT Foundation to conduct a global clinical studies to determine the potential for public market access in malaria-endemic countries of Africa and Asia. Over the next...

at 05:00
An estimated 2.3% of the European population is affected by bipolar disorder (BD)[1], a largely underestimated figure, since an average of 8-10 years passes between the appearance of symptoms and diagnosis[2]To date, the diagnosis of BD is based on a...

at 05:00
Dr. Decotiis noted, "Our practice is one of very few medical practices in New York that offer compounded tirzepatide for medical weight loss, as the nationwide shortage of the medication has put a strain on its availability. As a compounded...

at 04:35
SOLASCURE Ltd (SolasCure), a biotechnology company developing a hydrogel containing a recombinant enzyme derived from maggots which aims to accelerate wound debridement, has announced the completion of its GBP 10.9m (c. USD 13.3m) Series B investment...

News published on 30 january 2023 at 21:15 and distributed by: